<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-96640</identifier>
<setSpec>0214-9168</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Synthesis and purification of recombinant apolipoprotein apo A-I Zaragoza (L144R)</dc:title>
<dc:description xml:lang="en">Introduction Apolipoprotein A-I Zaragoza (apo A-I Z, L144R mutation) is an apolipoprotein A-I variant whose carriers have low HDL-cholesterol (HDL-c) concentrations but, paradoxically, no atherosclerotic symptoms despite the presence of additional atherogenic risks. In vivo metabolic studies performed on heterozygous carriers of this apo A-I variant revealed a two-fold increased fractional catabolic rate compared to the wild type protein, suggesting an enhanced effect on the overall reverse cholesterol transport process. Objectives To establish an expression and purification system of recombinant wild type apo A-I and apo A-I Z with high yield and purity in order to compare their properties related to reverse cholesterol transport as well as other anti-atherogenic characteristics. MethodsA cDNA clone of wild type apo A-I was used as a PCR template to amplify the mature peptide sequence. Specially designed primers allowed the cloning of the sequence into an inducible expression pET-45 plasmid adding a Histidine tag in the N-terminal expressed peptide. Site directed mutagenesis was used to produce the L144R mutation in the apo A-I sequence to be expressed in the same system. E. coli BL21(DE3) were transformed with the prepared plasmids, peptide expression was induced and purification was performed in non-denaturing conditions by nickel affinity chromatography. Results Expression and purification of both proteins was achieved and verified by SDS-PAGE and immunochemical procedures. Actual yields were over 30mg of purified protein per litre of culture and a 94% purity grade for the wild type protein and 93% for the mutant protein were obtained. Conclusions A system for the expression and purification of wild type apo A-I and apo A-I Z with high yield and purity grade has been set up. This will be the basis for future structural and functional characterization of the L144R apo A-I mutant allowing the study of its anti-atherogenic properties (AU)</dc:description>
<dc:creator>Pocoví Mieras, Miguel</dc:creator>
<dc:creator>Fiddyment Puertas, Sarah</dc:creator>
<dc:creator>García-Otín, Ángel-Luis</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción La apolipoproteína A-I Zaragoza (apo A-I Z, mutación L144R) es una variante de la apolipoproteína A-I cuyos portadores tienen muy baja concentración de colesterol-HDL (c-HDL) pero, aunque presenten factores de riesgo aterogénicos adicionales, paradójicamente no muestran signos de aterosclerosis a nivel subclínico. Estudios metabólicos in vivo realizados en los portadores heterocigotos de esta variante de apo A-I revelaron que tiene una tasa de catabolismo que duplica la de la proteína nativa sugiriendo la posibilidad de que tuviera un efecto favorable sobre el proceso global de transporte reverso de colesterol.Objetivo Establecer un sistema de expresión y purificación de apo A-I nativa y apo A-I Z recombinantes de alto rendimiento y elevada pureza con el fin de comparar sus propiedades en distintos aspectos relativos al transporte reverso de colesterol, así como otras características antiaterogénicas de la apo A-I. Metodología Partiendo del cDNA de apo A-I nativa se amplificó mediante PCR de la secuencia de la apo A-I madura y se diseñaron los oligonucleótidos cebadores que permitieron el clonaje en un plásmido de expresión inducible pET-45 que incorpora una cola de Histidinas en la posición N-terminal del péptido expresado. Mediante mutagénesis dirigida se introdujo la mutación L144R en la secuencia madura de apo A-I para expresarla con el mismo sistema. Bacterias E. coli de la cepa BL21(DE3) fueron transformadas con los plásmidos preparados, la expresión de las correspondientes proteínas fue inducida y su purificación realizada en condiciones no desnaturalizantes mediante cromatografía de afinidad en columnas de níquel. Resultados (..) (AU)</dc:description>
<dc:source>Clín. investig. arterioscler. (Ed. impr.);22(4): 146-153, jul.-ago. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-96640</dc:identifier>
<dc:title xml:lang="es">Síntesis y purificación de apolipoproteína apo A-I Zaragoza (L144R) recombinante</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d30252^s22001</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d23289^s22045</dc:subject>
<dc:subject>^d35408^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d931^s22002</dc:subject>
<dc:type>article</dc:type>
<dc:date>201008</dc:date>
</metadata>
</record>
</ibecs-document>
